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Integrated genomics and functional
validation identifies malignant cell
specific dependencies in triple negative
breast cancer
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Abstract
Triple-negative breast cancers (TNBCs) lack recurrent targetable driver
mutations but demonstrate frequent copy number aberrations (CNAs). Here,
we describe an integrative genomic and RNAi-based approach that identifies
and validates gene addictions in TNBCs. CNAs and gene expression
alterations are integrated and genes scored for pre-specified target features
revealing 130 candidate genes. We test functional dependence on each of
these genes using RNAi in breast cancer and non-malignant cells, validating
malignant cell selective dependence upon 37 of 130 genes. Further analysis
reveals a cluster of 13 TNBC addiction genes frequently co-upregulated that
includes genes regulating cell cycle checkpoints, DNA damage response, and
malignant cell selective mitotic genes. We validate the mechanism of
addiction to a potential drug target: the mitotic kinesin family member C1
(KIFC1/HSET), essential for successful bipolar division of centrosome-
amplified malignant cells and develop a potential selection biomarker to
identify patients with tumors exhibiting centrosome amplification.
Triple negative breast cancers harbor multiple copy number aberrations
driving gene expression changes thought to underpin their malignant
phenotypes. Here the authors integrate these features, finding and
functionally validating 37 gene addictions among which they identify the
mechanism of addiction to KIFC1, a potential selective drug target.
These contributed equally: Pierfrancesco Marra and Andrew N. J. Tutt.
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Introduction
Triple-negative breast cancers (TNBCs) are difficult to treat and lack expression
of the validated breast cancer therapeutic targets: estrogen (ER), progesterone
(PR), and human epidermal growth factor 2 (HER2) receptors[1]. TNBCs are
heterogeneous[2] with substantial numbers of patients in subgroups that have
high risk of early metastatic relapse commonly resistant to systemic therapy.
Despite frequent resistance, chemotherapy is the only widely accepted systemic
therapy option for these patients, highlighting the need to better understand the
underlying biology and identify tumor cell-specific therapy targets for drug
discovery or “repositioning” of known therapies.
Identification of tumor addictions (dependence on a gene for proliferation and
survival) has in the past led to the development of novel therapies, notably the
discovery of ERBB2 amplification and overexpression, now targeted by a
number of therapies in breast cancer[3]. Despite progress in characterizing the
genomic landscape of breast cancer[4, 5] and TNBC specifically[2, 6, 7, 8],
targetable biological dependencies remain elusive and poorly characterized.
With the exception of clonally dominant mutations in TP53, TNBCs
demonstrate a high degree of inter-tumor and intra-tumor heterogeneity at the
mutational level with each driver mutation only present in a subset of tumors
and clones within any individual tumor[9].
TNBCs have a high frequency of chromosomal instability resulting in variable
copy number state and levels of gene expression[7, 10]. Genes that are found in
amplified regions and are highly expressed, may be drivers of important
“hallmarks” of malignancy[11] and potentially represent essential tumor
addictions. A number of high-throughput loss of function screening studies have
identified gene addictions in cellular models of cancer including breast cancer
models[4, 5, 12] but functional validation has been limited and studies have
rarely been informed by evidence of upregulation of gene copy number or
mRNA in large numbers of patient tumors. Therefore, the main aim of this
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study is to identify and validate recurrently amplified genes as being important
for malignant phenotypes in TNBC. We perform a pre-specified integrative
computational “driver” identification and RNAi-based functional validation
approach, taking into account both the copy number landscape and whole
genome expression state in individual tumors, using a large discovery cohort of
TNBCs. We further couple this with clinical, functional and “druggability”
annotation to identify, cross reference in external data sets, and then
functionally validate, potential tumor addictions in TNBC.
As expected this approach identifies both known and novel genes that are
required for the survival of TNBCs. Interestingly, we identify clusters of genes
that are more frequently co-upregulated in TNBC. Within the largest cluster,
recurrent across external data sets, we focus on a potential drug target the
kinesin family member C1 (KIFC1/HSET) and show that KIFC1 is a selective
essential gene for many malignant breast cancer cells, demonstrating the
mechanism of addiction to be based upon clustering of abnormal multiple
centrosomes relevant to the majority of TNBCs that have centrosome
amplification[13]. Furthermore, we developed a potential centrosome
abnormality biomarker applicable to routinely fixed paraffin-embedded tumor
tissue to enable patient segmentation of those with cancers susceptible to
KIFC1/centrosome amplification targeted therapy.
Results
Identification of candidate gene addictions
In order to identify candidate tumor addiction genes, we interrogated the
genome-wide Affymetrix SNP6.0 copy number and Human Exon 1.0ST gene
expression profiles of 140 TNBC, 21 HER2-positive/ER-negative and 21
HER2-negative/ER-positive breast cancers, and 9 normal breast epithelium
samples[14, 15, 16]. All clinico-pathological features of the cohort are provided
in Supplementary Data 1. We obtained gene-centric copy number levels,
frequency and focality of gene copy number changes as well as the gene
expression from this cohort (Fig. 1a). The data were integrated with analyses of
publicly available databases such as COSMIC[17], the membranome[18], the
druggable genome[19], secretome[20], CAN genes[21], and kinome[22]
(Supplementary Data 2). All the above data were collated in the Target ID data
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platform that was used as a foundation for the application of a pre-specified
selection algorithm for putative addiction genes in TNBC.
Fig. 1
Integrative gene addiction identification and validation. Schematic representation
of bioinformatics based “Target ID” and functional validation RNAi experiment.
a Composition of the Guy’s TNBC-enriched cohort of breast cancers, used as a
source of DNA and RNA for this study. Two complementary approaches for
candidate gene addiction identification. In green, copy number-dependent gene
expression analysis shows initial filter for copy number gain/amplification and
correlation to gene expression and subsequent Target ID algorithm. This pipeline
consisted of a weighted scoring system for all genes based on copy number (CN),
gene expression (GEX), gene, and clinical annotation listed here and in the
Methods section. In purple, gene expression-centered analysis followed by
manual curation based on gene annotation and literature evidence of an
involvement in malignancy. b Workflow and hit selection criteria from primary
functional validation RNAi experiment. *Top 10 genes were subject to different
criteria as outlined in Results and Methods. c Example functional validation for
TTK, using pool of four siRNAs across panel of cell lines. Mean normalized
percent inhibition (NPI) from three independent experiments is plotted and error
bars represent the standard error of the mean (SEM), n = 3. d Example of data
from primary functional validation carried out in CAL51 cells. Data points
represent the mean NPI from three independent replicates. Dashed line represents
cut-off for positive hits at 18.01% NPI. e Mean NPI from CAL51 cell line after
deconvolution of pool of TTK siRNAs used independently. Error bars represent
SEM, n = 3. f mRNA knockdown of individual siRNAs in CAL51 cells.
Knockdown was evaluated by qPCR and represented as mean percentage of
knockdown compared to non-silencing control. Error bars represent SEM, n = 3
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The Target ID data platform informed two complementary approaches to gene
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selection for functional validation (mRNA overexpression and gene
amplification/ mRNA expression correlation) with the aim being to minimize
bias and limitations inherent to any single analytical procedure. First, a copy
number-dependent gene expression analysis selected 1978 candidate genes
amplified in >10% of TNBCs with a gene copy number/gene expression
correlation (r  > 0.3, p < 0.01, Spearman’s rank correlation). We then linked the
candidate genes to features, included in the Target ID data platform, which are
known to be relevant to hallmarks of malignancy in a weighted scoring system
(Fig. 1a and Supplementary Data 3). The top 85 genes were taken forward for
functional validation.
Second, a complementary gene expression-centered analysis was used as there
is evidence that variations in the expression of tumor addiction genes may also
occur in the absence of in cis CNAs through multiple mechanisms, for example
through epigenetic regulation[23]. For the gene expression-centered analysis,
we identified 1001 genes whose average expression in our TNBC cohort was
>2-fold higher than normal breast epithelium controls. As anticipated by the
inclusion of CNA correlated elevated gene expression in the first approach there
was a substantial overlap with 45 of the genes from the second approach which
were taken forward for functional validation. An additional 45 genes identified
by this second approach were selected based exclusively on gene annotation and
literature review. This manually curated filtering sought to identify genes
already shown to drive a tumor phenotype in other cancer models or being
involved in biological pathways known to be key in cancer development and
progression. In total our approaches identified 130 candidate tumor addiction
genes (Fig. 1a) with a high degree of overlap with both TCGA[6] and
METABRIC[7] data sets and (Supplementary Datas 4 and 5).
Functional validation of candidate genes using RNAi
To assess the role of each of the 130 candidate gene addictions in the
proliferation and viability of cancer cells, siRNA knockdown and cell viability
assays were carried out in breast cancer cell lines( BCCLs). In order to increase
the feasibility of the initial candidate screening experiment, each gene was
silenced in a gene-specific subset of 6–9 BCCLs (out of a panel of 16) and the
non-malignant HMEC normal breast epithelial cell line. Expression levels of
each gene were analyzed in our cell line cohort based on previously described
2
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mRNA analyses[14, 24]. Cell lines were selected for each gene to capture the
widest possible range of expression levels of each gene (Supplementary
Figure 1 and Supplementary Data 6).
As candidate genes were assessed across multiple cell models, normalized
percent inhibition (NPI) of growth was used to compare data obtained from
multiple experiments with different cell lines. Repeated measures of the NPI of
negative controls across all cell lines showed a mean of 0.18% with a standard
deviation of 5.94 (Supplementary Figure 2a). Therefore, the knockdown of a
gene was considered as having a growth inhibition effect on a cell line, if its
knockdown achieved an NPI ≥ 18.01% (three standard deviations above the
mean).
Based on highest scores from the Target ID algorithm, literature review and
expert opinion a group of 10 genes amongst the 130 candidates (Top 10—see
Fig. 1b) were selected as being more likely to be associated with a malignant
cell-specific addiction in TNBC and were expedited for multiple single oligo
RNAi analysis of effect on phenotype with validation of gene knockdown from
the outset. For these genes, a prioritized validation procedure was employed
which involved independent testing of three individual siRNAs per gene for
evidence of gene knockdown by qPCR in relation to phenotypic effect in a
proliferation assay. We aimed to identify genes that, rather than being essential
for the viability of all cells, showed growth inhibition effect on some but not all
cancer cells indicating some selectivity for an underlying biological context and
malignant phenotype. Therefore, genes from this “top 10” group were
considered a “hit”, if two siRNAs that showed a knockdown >70% did not
affect the growth of HMEC, but did inhibit the growth of at least two cancer
cell lines. We identified seven genes (FZD6, MASTL, NCSTN, PTK2, PTP4A3,
SEC61G, and UBE2T) from this group as being putative tumor addiction genes
(Supplementary Datas 4 and 7).
The remaining 120 genes identified through the integrated analyses underwent a
two-stage functional validation process. First, each gene was assessed using a
pool of four siRNAs. A gene was considered a “hit” if its silencing inhibited
growth in at least two cancer cell lines whilst having no effect on HMEC. By
example, we declared TTK/MPS1, a previously validated mitotic target[25], as a
“hit” by these criteria in the screen (Fig. 1b–d). As HMEC themselves may have
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developed dependencies as a result of “in vitro” 2D culture on plastic, we also
considered a gene a “hit” if it showed an effect on HMECs, but had a
heterogeneous effect across the cell line panel with no effect in at least two
cancer cell lines indicating that the gene was not essential for all dividing cells.
Primary validation revealed 64 potential tumor addiction genes (Supplementary
Datas 4 and 8 and Supplementary Figure 2b).
To identify and discard false positive “hits” that were in fact due to off-target
effects within our RNAi pools, we performed a secondary functional validation
step. This required there to be consistency between relative mRNA knockdown
and cell viability changes for each of the four siRNAs used independently
(selection criteria are described in detail in Online Methods) (Fig. 1e,f). Of the
64 genes, 30 fully met these secondary functional validation criteria, and 34
failed (Supplementary Datas 4 and 9).
Overall, the primary and secondary RNAi-based functional analyses have
validated 37 tumor addiction genes (7 from the “top 10” and 30 of the
remainder (Supplementary Figure 3 and Table 1.) All “out of patient” functional
validation models have their caveats. The stress of cell culture may change
relationships between gene expression and CNAs and cell addiction in
comparison to that in the patient. Although our identification of these genes in
genomics data was based on integrated copy number and gene expression with
evidence of overexpression or CNA-driven expression in patient primary
tumors, we believe that a requirement for linkage of amplification or level of
gene expression with phenotype in 2D cell cultures would be a poor validation
criterion for identifying selective dependencies. Rather we require
heterogeneity of siRNA effect on a gene across multiple cell lines, including a
non-malignant model, followed by validation of linkage between phenotype and
mRNA depletion across multiple siRNAs for these 37 genes believing this to be
a better criterion to find selective tumor addictions, as opposed to non-selective
obligate requirements for a gene for cell growth in all cells. The targeting of the
latter gene would be expected to create adverse effect in normal tissues in
patients. Despite the caveats raised above, for completeness, we show the
depletion induced phenotype of each validated gene in each cell line used
showing that cell line’s expression of the gene relative to transformed but non-
malignant HMEC cells. We found 10 out of the 37 genes selected based on our
criteria also had evidence of gene dependency only in cell lines with levels of
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gene expression greater than that of HMECs (Supplementary Figure 4).
Table 1
Functional annotation of validated genes
 
The 37 functionally validated genes and their manually curated gene annotation
of biological function using the GeneCards Suite[26]. Red, tumor gene
addictions novel to cancer, orange, tumor gene addictions novel to breast cancer
Identification of functional clusters required by TNBC
Literature review, the GeneCards database[26] and gene annotation analyses of
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these 37 genes revealed involvement in the cellular processes of cell cycle
regulation, DNA damage response, epigenetic regulation, metabolism,
proteasome function, protein sorting, signaling, and vesicle trafficking
(Table 1). To understand coordinated upregulation that might drive the biology
of TNBCs we interrogated the pattern of amplification/upregulation of these
genes, across our tumor cohort and, for external validation, in public databases.
Among the 37 genes, we found as expected genes that frequently had their copy
number levels correlated when they reside in close proximity in the genome
(Fig. 2a). We sought to identify co-upregulation of genes which are not in the
same amplicon or in close vicinity and so performed pairwise gene to gene
expression correlation, through which a set of 13 highly co-upregulated genes
was identified (Fig. 2b). Using the expression levels of these 13 genes to create
a composite score clearly identified a population of ~88% of TNBC patients
with a high expression of this score (Supplementary Figure 5a, b). This high
scoring population contains all the basal-like 1, basal-like 2, and
immunomodulatory Vanderbilt TNBC subtype[2] tumors but does not exclude
other types (Supplementary Figure 5c). These 13 genes are involved in the
regulation of the transcription of cell cycle progression genes (FOXM1, LIN9,
and MYBL2)[27], in the DNA damage response pathway (CHEK1, DTL,
RHNO1, and UBE2T)[28, 29], and in mitosis (Fig. 2c). Among these malignant
cell selective addiction genes associated with mitosis MASTL regulates mitotic
entry[30], BUB1, BUB1B, NUF2, and TTK act as part of the spindle assembly
checkpoint[31], and KIFC1 has been shown to play an essential role in
centrosome clustering to regulate bipolarity during mitosis[32]. These data were
supported by analysis of publicly available data sets (Supplementary Figure 5d–
g) where we found 10 genes (BUB1, CHEK1, DTL, FOXM1, KIFC1, LIN9,
NUF2, RHNO1, TTK, and UBE2T) concordant between analyses of our data and
in the METABRIC study dataset. Moreover, when we investigated the 5′
upstream regions of these genes and identified an E2F8 transcription factor
binding site in 8 out of 13 genes, namely KIFC1, MYBL2, TTK, CHEK1,
FOXM1, NUF2, UBE2T, and MASTL (Supplementary Figure 5h). Expression
levels of E2F8 were highly correlated with each of the eight genes and might
point to a common transcriptional activation network that further enhances the
copy number-dependent expression of these genes.
Fig. 2
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A subset of tumor addiction genes that are co-upregulated have roles in cell cycle
progression, mitosis and DNA damage response. Copy number (a) and gene
expression (b) levels of 37 tumor addiction genes were pairwise correlated and
tested for statistical significance using Pearson method in the TNBC tumors of the
Guy’s TNBC-enriched cohort (n = 82). Their correlation coefficients were
hierarchically clustered using Ward distance method, and displayed as levelplots.
In the gene expression correlation heatmap highly correlated genes are
surrounded by black rectangles, representative of underlying clusters from
hierarchical clustering method whereas a cross denotes insignificant p-value as
per level of 0.05. c Interconnectivity among the 13 co-upregulated tumor
addiction genes is displayed based on STRING networks. Genes with shared
functional roles are outlined
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Although many cancer therapeutics target the mitotic apparatus, the ability to
selectively impact mitosis in malignant cells has largely evaded drug discovery
efforts. There is evidence that KIFC1, a potentially druggable ATP-dependent
motor protein[33], is involved in tumorigenesis through its ability to cluster
extra centrosomes in centrosome-amplified cancer cells. In addition,
centrosome amplification is a major cause of aneuploidy and genomic
instability[34] all of which are highly prevalent in breast cancers[35].
Therefore, we focused on the validation of KIFC1 CNAs and expression in
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external data sets and the further investigation of its function in the malignant
cell-specific dependency in TNBC.
The heterogeneous effect of silencing KIFC1 across the panel of seven cell lines
used for its primary and secondary functional validation (Fig. 3a), suggests a
mechanism-specific dependency rather than simply a requirement for this
kinesin motor protein in all highly proliferative cells. Our secondary functional
validation by deconvolution of the siRNA pool, with demonstration of effect of
all four siRNAs in the pool and proof of knockdown, reduce the likelihood the
phenotype is caused by an off-target effect of an siRNA (Fig. 3b, c).
Fig. 3
KIFC1 is a validated tumor addiction gene that is upregulated in TNBCs. a
Primary pooled siRNA oligo validation data for KIFC1. Mean NPI are plotted and
error bars represent the SEM, n = 3. b Mean NPI from three independent of
HCC1143 cell line after deconvolution of pool of KIFC1 siRNAs used
independently. Error bars represent SEM, n = 3. c mRNA knockdown of
individual siRNAs in HCC1143 cells. Knockdown was evaluated by qPCR and
represented as percentage of knockdown compared to non-silencing control from
three technical replicates. d Copy number alterations of KIFC1 correlated with its
gene expression across all breast cancers in the Guy’s TNBC-enriched cohort of
breast cancers, (e) TCGA BRCA and (f) METABRIC data sets. g KIFC1 gene
expression across the PAM50 breast cancer subtypes in the Guy’s TNBC-enriched
cohort of breast cancers, (h) TCGA BRCA and (i) METABRIC data sets. Box-
and-whisker plots showing median center line, 25% and 75% box limits and range
of expression, non-paired two-sided Wilcoxon rank sum test; *p < 0.05, ****p < 
0.0001
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We next sought confirmation of the relationship between KIFC1 CNA and gene
expression in external and independent TCGA Breast and METABRIC data
sets[6, 7] and observed a direct correlation between KIFC1 gene expression and
gene copy number similar to that seen in our own discovery cohort (Fig. 3d–f).
In addition, to investigate if KIFC1 expression is breast cancer subtype specific,
its expression levels were analyzed across PAM50 breast cancer subtypes,
demonstrating higher levels of KIFC1 in the basal-like subtype, known to have
significant overlap with, and forming the dominant subtype within, TNBC
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(Fig. 3g–i).
Centrosome amplification sensitizes cells to KIFC1 silencing
KIFC1 has been shown to play a role in centrosome clustering, generation and
maintenance of bipolar mitosis in cells exhibiting supernumerary
centrosomes[32, 36]. To determine whether the dependency of our breast cancer
models on KIFC1 was related to the degree of centrosome abnormality they
demonstrate, 11 cell lines were scored for the proportion of cells with
centrosome amplification and subsequently tested for functional dependency on
KIFC1 by using RNAi. CAL51, HCC38, CAMA1, SUM149, and the non-
malignant breast cell line, HMEC, had low levels of centrosome amplification
(0–7%), while BT20, MDA-MB-231, MCF-7, HCC1143, HCC1954, and
SKBR3 showed relatively high levels of centrosome amplification (18–60%)
(Fig. 4a, b).
Fig. 4
KIFC1 is specifically required for survival of cancer cells exhibiting centrosome
amplification. a Centrosome amplification (CA) scores for panel of breast cancer
cell lines. Cell lines were dichotomized into low CA (black) and high-CA (red)
groups. b Representative immunofluorescence images showing centrosome
marker Aurora A (green) and centriole marker CP110 (red) used for calculating
CA score. Scale bar is 5 µm. Top right inset shows red channel, bottom right inset
for each image shows green channel. c Mean normalized percent inhibition (NPI)
of panel of cell lines dichotomized into low and high-CA groups for siRNA #2,
#4, #5, and #6. Error bars represent the SEM, n > 3. Student's t test: **p < 0.01,
***p < 0.001, ****p < 0.0001. d Plots are missing units of measurement (%) on
the y-axis. Same as in figure 4f (below).  Colony formation assay of two low
centrosome-amplified cell line (CAMA1 and SUM149) and two high-centrosome-
amplified cell lines (MDA-MB-231, HCC1954 and BT20) infected with either
non-targeting shRNA (NT) or shRNA-targeting KIFC1 (KIFC1 shRNA). Cells
were grown for 14–21 days in the presence or absence of doxycycline, fixed and
stained in crystal violet and colonies quantified. Mean surviving fraction
normalized to NT, error bars represent the SEM, n = 3. One-way ANOVA with
Tukey’s multiple comparisons test: ***p < 0.001, ****p < 0.0001. e NPI of MDA-
MB-231 cells infected with either GFP alone (GFP) or GFP-tagged RNAi-
resistant KIFC1 (GFP-KIFC1 ) with KIFC1 siRNA #4 and #6. Error barsr
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represent the SEM, n = 3, one-way ANOVA with Tukey’s multiple comparisons
test: *p < 0.05, **p < 0.01. f Colony formation assay of MDA-MB-231 cells
infected with inducible KIFC1 shRNA and infected with inducible RNAi-resistant
HA-tagged KIFC1 (KIFC1-HA ) or with empty vector (EV) control. Mean
surviving fraction normalized to NT, error bars represent SEM, n = 3. One-way
ANOVA with Tukey’s multiple comparisons test: ****p < 0.0001. g MDA-MB-231
graph on left is missing units (mm ).  Nude hosts were orthotopically injected with
either MDA-MB-231 or HCC1954 cells with inducible KIFC1 shRNA and were
treated with (red) or without (black) doxycycline when tumors reached >2 × 2 mm
(4.2 mm ). Mean tumor volumes at time points indicated, error bars represent the
SEM, from two independent experiments. Two-way ANOVA with Sidak’s
multiple comparisons test: *p < 0.05, **p < 0.01, ****p < 0.0001
r
3
3
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Four independent siRNA oligos, validated to deplete KIFC1 mRNA and/or
protein (Supplementary Figure 6a, b), induced a substantial reduction of cell
viability over a 6-day period only in the cell models with centrosome
amplification, regardless of breast cancer subtype (Fig. 4c). KIFC1 knockdown
showed an even greater impact in a long-term clonogenic survival assay (14–21
days) in centrosome-amplified cell lines, MDA-MB-231, HCC1954, and BT20
using an independent shRNA sequence targeting KIFC1 in an inducible
expression system (Fig. 4d; Supplementary Figures 6c, 9). In contrast, no
significant reduction in clonogenic survival was seen in the CAMA1 cell line,
which has low levels of centrosome amplification (one-way ANOVA with
Tukey’s multiple comparisons test).
To further exclude the possibility that, despite using multiple RNAi approaches,
the observed phenotype was due to an “off target” effect, we performed a rescue
of function experiment by over-expressing an RNAi-resistant GFP-tagged or a
HA-tagged KIFC1 protein (GFP-KIFC1 /KIFC1 -HA) in MDA-MB-231 cells.
As shown in Fig. 4e, reduction in cell viability by KIFC1 siRNA knockdown
was rescued by the presence of GFP-KIFC1  (Supplementary Figure 6d).
r r
r
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Similarly, the long-term clonogenic survival phenotype was rescued in the
presence of KIFC1 -HA following knockdown with shRNA (Fig. 4f;
Supplementary Figure 6e), confirming the specificity of the dependency on
KIFC1.
We subsequently examined the consequence of KIFC1 silencing on the tumor
growth of centrosome-amplified cell line xenografts with MDA-MB-231 and
HCC1954 cells in vivo. Using an inducible shRNA expression system with
KIFC1 shRNA doxycycline-induced KIFC1 depletion resulted in significant
tumor growth inhibition in both cell lines (Fig. 4g) in contrast to non-targeting
(NT) control cell xenografts (Supplementary Figure 7a) (two-way ANOVA with
Sidak’s multiple comparisons test). KIFC1 depletion in tumors was confirmed
by immunohistochemistry (IHC; Supplementary Figure 7b). We hypothesized
that the ability of mitotic cells to cluster supernumerary centrosomes into a
bipolar mitosis in xenograft tumors would be impaired by KIFC1 silencing.
Histological analysis of centrosomes by pericentrin (an integral component of
the pericentriolar material) by IHC and identification of mitotic cells by nuclear
counter staining (Supplementary Figure 7c), confirmed that loss of KIFC1
resulted in a reduction in the proportion of mitoses in centrosome-amplified
cells where cells were capable of clustering their centrosomes into two poles
(bipolar), 4 days after the start of treatment in both cell lines (Supplementary
Figure 7d).
KIFC1 silencing causes multicentrosome multipolar mitosis
To investigate the mechanism by which centrosome-amplified breast cancer
cells are “addicted” to KIFC1, comparative immunofluorescence imaging of the
mitotic spindle was performed in three cell lines with low levels of centrosome
amplification and five cell lines with relatively high levels of centrosome
amplification. As shown in Fig. 5a, b, tThere was a marked increase in the
number of mitotic spindle poles per cell and consequent multipolar mitoses in
the cell population when KIFC1 was knocked down in the centrosome-
amplified cells (Fig. 5a, b).
Fig. 5
Cell lines with centrosome amplification undergo multipolar mitoses followed by
mitotic catastrophe in the absence of KIFC1. a Representative
r
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immunofluorescence images of mitotic spindles in low-CA cell line (CAL51) and
high-CA cell lines (HCC1143 and SKBR3) with control or KIFC1 siRNA or mock
transfection. Spindles stained with Aurora A (green) and/or Eg5 (red). Scale bar is
5µm. b Mean percentage of multipolar mitotic cells. Error bars represent the
SEM, n = 3. c Images of time-lapse of MDA-MB-231 cells expressing NT shRNA
showing a bipolar mitosis. d Images of time-lapse of MDA-MB-231 expressing
KIFC1 shRNA showing prolonged mitosis and subsequent apoptosis. e. Images of
MDA-MB-231 cells with inducible KIFC1 shRNA showing an abnormal
multipolar mitosis. Scale bar is 5 µm
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Next, using live cell time-lapse imaging of MDA-MB-231 cells, we investigated
the fate of cells undergoing multipolar mitosis during knockdown of KIFC1. We
demonstrated that KIFC1 knockdown arrested cells in mitosis for a prolonged
period, compared to a normal bipolar mitosis (Fig. 5c; Supplementary Movie 1),
and consequently caused the cells to either undergo mitotic catastrophe (Fig. 5d;
Supplementary Movie 2) or to fail cytokinesis and remain in a multinucleated
state (Fig. 5e; Supplementary Movie 3). The druggability of KIFC1 has
previously been shown where the KIFC1 inhibition tool compound, AZ82, is
predicted to contact the L5 loop in an ATP competitive manner and showed a
signal of efficacy in centrosome declustering but had poor target potency and
had many off-target non-centrosome amplification selective cytotoxic
effects[33]. We have confirmed this (Supplementary Figure 8) precluding its
further use in our work but raising the possibility of discovery of more potent
and specific KIFC1 kinesin motor inhibitors.
Induced centrosome amplification increases KIFC1
dependency
KIFC1 depletion in vivo resulted in a clear reduction in tumor growth but not
total inhibition of growth. As there is no specific and potent KIFC1 motor
inhibitor we used inducible shRNA interference to deplete KIFC1 expression.
Using RNAi, continued function of a small amount of residual protein is likely
to limit efficacy in comparison to a drug. In addition, non-centrosome-amplified
sub-populations of cells may be unaffected and persist leading to a growth
impaired but viable tumor. We therefore sought to augment the effect of KIFC1
depletion by combining it with a clinically relevant therapy capable of further
induction of centrosome amplification in tumor cells. Platinum-based
chemotherapies are currently considered one of the standard of care treatments
for advanced TNBCs[37] and cisplatin is known to cause centrosome
amplification by decoupling the centrosome duplication cycle from the DNA
replication cycle[38]. We found that MDA-MB-231 cells show an increase in
centrosome amplification when treated with increasing concentrations of
cisplatin (Fig. 6a). We therefore hypothesized cisplatin would increase cellular
dependency on KIFC1 and by normalizing colony formation assays to vehicle
control in the presence or absence of doxycycline, we show synergy beyond
additivity between the effect of cisplatin treatment and inducible shRNA-
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induced KIFC1 depletion (Fig. 6b, c) consistent with the increase in centrosome
amplification induced by cisplatin.
Fig. 6
Therapeutic induction of centrosome amplification in tumors increases the
efficacy of KIFC1 silencing. a MDA-MB-231 cells were treated with five serial
concentrations of cisplatin and DMSO control and scored for centrosome
amplification (CA). Table shows the level of CA at each concentration of
cisplatin. b Surviving fraction of MDA-MB-231 cells with inducible NT shRNA
with (red) or without (black) doxycycline. Data points represent the mean, error
bars represent the SEM, n = 3. Extra sum-of-square F-test (F-value 0.41). Right,
representative images of colony formation wells for each treatment condition. c
Surviving fraction of MDA-MB-231 cells with inducible KIFC1 shRNA with
(red) or without (black) doxycycline. Data points represent the mean, error bars
represent the SEM, n = 3. Extra sum-of-squares F-test (F-value 57.59). Right,
representative images of colony formation wells for each treatment condition.
Note, five times more MDA-MB-231 cells with KIFC1 shRNA (Dox) were plated
due to low colony forming ability of cells without KIFC1. d Nude hosts were
injected with MDA-MB-231 cells with inducible KIFC1 shRNA and were treated
with or without doxycycline and either vehicle or 5 mg kg  of cisplatin when
tumors reached >2 × 2 mm or 4.2 mm . Mean tumor volume at time points
indicated, error bars represent the SEM, from two independent experiments. Two-
way ANOVA with Tukey’s multiple comparison test: **p < 0.01, ****p < 0.0001
(only shown for final time point). e Nude hosts were injected with MDA-MB-231
cells with inducible KIFC1 shRNA and were treated with either vehicle or 5 mg 
kg  of cisplatin when tumors reached >33 mm . Tumors taken 4 days after start
of treatment in the no dox group were stained with pericentrin by IHC and the
percentage of abnormal centrosomes was scored for vehicle and cisplatin
treatments arms. Mean percentage of cells with centrosome abnormalities, error
bars represent the SEM, n = 4. Student's t test: *p < 0.05
−1
3
−1 3
27/02/2018, 19*25e.Proofing
Page 25 of 51http://eproofing.springer.com/journals_v2/printpage.php?token=gIpUBAqoUnLev8_6EejHUDGvy2wo5Qtu58sEP6vNEnM
We investigated the combination of cisplatin treatment and KIFC1 silencing in
MDA-MB-231 cell line xenografts again using an inducible shRNA expression
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system. Cisplatin treatment led to sensitization to KIFC1 silencing compared to
cisplatin or KIFC1 silencing alone (Fig. 6d) consistent with the synergistic
effect seen in vitro in the same model. Pericentrin staining of MDA-MB-231
xenografts after 4 days of cisplatin treatment revealed significantly increased
centrosome abnormalities as compared to vehicle treated tumors in the absence
of doxycycline (Fig. 6e) (Student's t test).
A potential biomarker for tumor addiction to KIFC1
function
Use of immunofluorescence-based scoring of the percentage cells with
centrosome amplification that we used in cell lines may be impractical as a
predictive biomarker for KIFC1 motor silencing in patient formalin-fixed
paraffin-embedded (FFPE) tumor material, because individual cells cannot be
assessed throughout their volume and centrosomes are frequently lost outside
the plane of the histological section. Centrosomes cannot be accurately counted
and assigned to any individual cells. Therefore, we sought to develop a
potential predictive biomarker based on identification of centrosome
abnormalities in a light microscopy “field of view” using a pericentrin IHC
assay. We developed an automated scoring system for analyzing the size of
pericentrin stained centrosomes detected by IHC in interphase cells in FFPE
tissue. Using image analysis, we sought to define the average size of a
centrosome body in a normal breast tissue section (Fig. 7a) finding this to be
1.44 µm  with the largest normal breast epithelial cell centrosome body being 7 
µm . We then set this as the cut-off for the upper limit of normal pericentrin
stained centrosome size. A pericentrin staining body of greater size than this
was termed “abnormal”. Based on this approach, we developed a pericentrin
abnormality (PCAB) score, which we defined as the percentage of abnormal
pericentrin stained bodies over total stained bodies in a whole section of FFPE-
embedded cell line pellets or tumor sections. We subsequently compared
centrosome body size and PCAB score in breast tumor sections that a
pathologist determined demonstrated “normal” or “abnormal” centrosomes. We
found that the former (Fig. 7b) had a centrosome body size and PCAB score in
the range of that of normal breast tissue in contrast to the latter where our
automated method correctly detected a higher PCAB score due to a number of
“abnormal” pericentrin stained centrosome bodies within the field of view
(Fig. 7c).
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Fig. 7
Pericentrin abnormality score: a potential predictive biomarker for sensitivity to
KIFC1 inhibition. a Normal breast tissue section stained for pericentrin as a
centrosome marker and below, a scatter graph of DAB staining area versus DAB
mean intensity. Cut-off for normal centrosome size was set at 7 µm . b Tumor 1
with centrosomes that appear normal. Below, scatter graph of DAB staining area
vs DAB mean intensity showing a PCAB score of 1.19%. c Tumor 2 with
centrosomes that appear abnormal. Below, scatter graph of DAB staining area vs
DAB mean intensity showing a PCAB score of 12.34%. d PCAB score vs NPI
(%) upon KIFC1 silencing across panel of breast cancer cell lines. Linear
regression analysis, r  = 0.71, p < 0.05. Scale bars represent 25 µm. e. PCAB
score of TMAs of cohort of 82 TNBCs. Dashed red line depicts the median PCAB
score (32%) of breast cancer cell lines sensitive to KIFC1. f Kaplan–Meier curves
illustrating the duration of recurrence free survival according to a 20% PCAB cut-
off. Wald test, p < 0.05, hazard ratio (HR) = 1.95, confidence intervals (CI) = 1–
3.89
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When the PCAB score was calculated in breast cancer cell line (BCCL) pellet
FFPE blocks from lines previously characterized for KIFC1 dependency this
revealed a linear correlation between PCAB score and the NPI caused by
KIFC1 knockdown (Fig. 7d). In order to ascertain the proportion of TNBCs that
might show centrosome amplification at a level we associate with KIFC1
dependency in vitro, automated PCAB scoring was performed on a panel of
FFPE primary TNBCs. We found 63% of tumors had a PCAB score above 20%,
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above which no KIFC1-insensitive cell line was scored (Fig. 7e). This suggests
that a substantial proportion of TNBCs have centrosome amplification at a level
that may be associated with addiction to the centrosome clustering functions of
KIFC1. The data also indicate patients with a high-PCAB score (>20%) had a
shorter time to recurrence in the Guy’s TNBC-enriched cohort (Fig. 7f).
Discussion
A number of comprehensive analyses have documented the genomic landscape
of breast cancers and associated mutations, copy number variations and gene
expression patterns but very few of these genomic features have been subjected
to functional validation for their selective requirement for growth or other
malignant phenotypes in breast cancer model systems[5, 12]. TNBCs have few
known targetable addictions[8, 39] and are dominated by copy number
aberrations (CNAs) with in cis or in trans associated gene expression changes[7,
10]. We have used a discovery cohort of triple-negative enriched primary breast
cancers and employed a pre-specified systematic integration of copy number
and gene expression data within each tumor to identify and functionally validate
genes, the expression of which are required for growth of cell models of breast
cancer but not required by all proliferating cells.
Our analysis led to the identification of 37 functionally validated genes,
(Table 1) many of which are novel, as well as confirmation of several known
addictions in breast cancer that validate our approach.
Our findings identify a number of known oncogenes such as BUB1, BUB1B,
and CHEK1 and less known and characterized gene addictions in TNBC such as
FANCL, GABRP, GNB4, NUF2, and VPS45 which we find validated in other
data sets[4, 5]. Furthermore, comparison of validated hits and data from the
COLT-Cancer data[12] found concordance between our siRNA NPI scores and
the zGARP shRNA scores for 11 genes (BUB1B, CHEK1, FOXM1, GABRP,
MYBL2, PRKDC, PSMD4, S100A9, GPR89, FANCL, GNB4) (Supplementary
Data 11). As expected given the differences in RNAi methodologies, phenotypic
endpoint and lack of validation of knockdown effects of RNAi in the COLT-
Cancer screen we observed little statistical correlation between the results
overall[12].
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A correlation analysis showed several co-amplification and co-expression
patterns across our tumors. Genes that were frequently co-amplified because of
their association with the same amplicon, were not necessarily also co-
upregulated. Interestingly 13 genes belonging to different amplicons and
chromosomes showed a higher correlation in mRNA expression. Our data
suggest that as well as being individually essential for TNBC survival, a
substantial proportion of TNBCs rely on the function of specific genes within
common cellular processes: such as the DNA damage response (CHEK1, DTL,
RHNO1, and UBE2T); transcriptional regulation of the cell cycle as in the case
of FOXM1, LIN9, and MYBL2 which control the DREAM/LINC complex
known to regulate entry/exit from quiescence and cancer cell proliferation[27];
and mitosis (BUB1, BUB1B, KIFC1, MASTL, NUF2, and TTK). Interestingly,
CHEK1, DTL, and MASTL are implicated in the G2 checkpoint, while NUF2,
BUB1, TTK, and BUB1B control the mitotic spindle assembly checkpoint.
In addition, this correlation analysis revealed cancer-specific addiction
associated with coordinated upregulation of another subset of genes that reside
in the same region of chromosome 1 and are involved in vesicle and protein
trafficking (GBA, GPR89A, NCSTN, PSMD4, VPS45). Indeed, gene annotation
analysis of the 37 functionally validated hits indicated others involved in
vesicle and protein trafficking (SEC61G, TTC35, and NRDG1). Alteration of
these processes have been suggested to be a causative event in cancer
development[40].
The largest of the clusters arising from the STRING protein interaction database
network analysis identified malignant cell-specific dependencies on groups of
mitosis and cell division control genes. Most basal-like cancers, which
substantially overlap with TNBCs, exhibit high expression of proliferative
genes and have a higher mitotic index than other breast cancer subtypes[41, 42,
43]. Importantly we find that knockdown of these genes is dispensable in non-
malignant cells as well as some rapidly proliferating cancer models suggesting a
specific requirement for the genes in these clusters due to selective addiction
rather than an essential function in cell cycle progression and mitosis in all
proliferating cells. Furthermore, the METABRIC study identified a common
trans-acting chromosome 5q deletion that resulted in altered expression of
signaling molecules and cell division genes in breast cancers of the intClust 10
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subtype[7]. These genes include AURKB, BUB1, CHEK1, FOXM1, KIFC1, and
TTK[7], five of which, BUB1, CHEK1, FOXM1, KIFC1, and TTK, we have also
identified and have functionally validated to have a selective requirement for
cell growth in breast cancer cell models. The TTK/MPS1 kinase, is a druggable
mitotic checkpoint kinase that has already been identified as a malignant cell
selective target the depletion or inhibition of which causes failure of cell
population growth associated with PTEN pathway deficiency[25]. The
identification and functional validation of TTK/MPS1 is consistent with PTEN
loss of function being a common feature of TNBC and its cell models and
provides validation of our approach.
Targeting mitosis and cell division as an anti-cancer strategy is not novel and
has been the basis of successful systemic microtubule targeting chemotherapies
such as the taxanes, vinca alkaloids, and eribulin. However, the impact on
patient benefit has been constrained by the fact these agents have substantial
normal tissue toxicity due to effects in non-malignant tissues with high cellular
turnover leading to a narrow therapeutic window. In contrast the specificity of
the dependency on the KIFC1 kinesin to centrosome-amplified cancer cells
offers the possibility of a potentially druggable malignant cell-specific target
and a mechanism-based patient selection biomarker of centrosome abnormality
that can be applied to routinely collected formalin-fixed tumors. In a non-
malignant setting, KIFC1 is not required for the faithful division of somatic
cells[44] suggesting its inhibition would be well tolerated by non-malignant
tissues in patients; however, as it is known to play a role in spermiogenesis and
oocyte development[45] possible germ cell toxicity may be anticipated. In a
malignant setting, KIFC1 expression has been correlated with poor prognosis in
breast cancer[46], and higher level expression is observed in ovarian
adenocarcinoma patients[47] and in other cancer types, including glioblastoma,
lung, colon, and cervical tumor samples when compared to corresponding
normal tissues. Although the centrosome clustering-independent mechanisms
have been suggested to be relevant to KIFC1 addiction in breast cancer[48], we
find across multiple model systems that there is a strong dependency on the
centrosome clustering function of KIFC1 by detection of mitotic catastrophe
and correlation of centrosome amplification with sensitivity to KIFC1
depletion. KIFC1 expression in non-small cell lung carcinoma was found to be
highly predictive of the development of brain metastasis in both early and
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advanced disease[49] suggesting association of expression with highly
aggressive forms of common cancers.
Effects of KIFC1 on treatment resistance may contribute to poor prognosis. It
has been shown that KIFC1 overexpression is correlated with resistance to the
mitotic spindle-stabilizing agent docetaxel[50]. A possible explanation of these
findings is based on recent evidence showing that the mechanism of action of
clinically relevant doses of paclitaxel is through induction of multipolar
mitosis[51, 52] raising the possibility that a KIFC1-dependent mechanism of
microtubule-organizing center re-clustering may be involved in the
development of taxane resistance.
Our data show that inhibiting KIFC1 in BCCL models leads to cell population
growth arrest both in in vitro culture and in vivo models, and that this is specific
to centrosome-amplified cells. This is supported by previous findings in non-
breast cancer isogenic cell line model systems with artificially induced
centrosome amplification[36]. Centrosome amplification is a well-characterized
phenomenon that is specific to cancer cells, first described by Theodor Boveri
over a 100 years ago[53]. Since then studies have identified that centrosome
amplification is sufficient to initiate tumorigenesis[34, 54] and that centrosome
amplification can also mimic the effects of oncogenes in triggering cellular
invasion[55]. Therefore, targeting centrosome-amplified cells by KIFC1
inhibition would be expected to have effects in many cancer types. To identify
tumors with centrosome amplification we have also presented the preliminary
development of a method, PCAB, which quantifies centrosome features in
excess of those of normal tissue cells that might be used to stratify patients and
predict a population that appear to have adverse prognosis and may benefit from
inhibition of the KIFC1 kinesin motor. We show that this PCAB score
developed in malignant and normal breast tissue identifies a large proportion of
TNBC patients with centrosome amplification who have poor prognosis and
associates with KIFC1 addiction in breast cancer cell models.
Our in vivo studies showed a significant growth inhibition of KIFC1-depleted
centrosome-amplified cell xenografts (two-way ANOVA with Sidak’s multiple
comparisons test). The fact that our inducible shRNA in vivo model depletes but
does not completely ablate the expression of KIFC1 may explain why inducible
expression of KIFC1 shRNA impairs but does not eradicate the tumor. This
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highlights the potential value in now developing potent and selective small
molecule KIFC1 motor inhibitor compounds and examining their efficacy in
preclinical models. We have demonstrated a synergistic effect between KIFC1
silencing and cisplatin treatment, a therapy that induces centrosome
amplification in cancer cells, on long-term clonal growth in culture and in vivo
xenografts growth suggesting potential for combination approaches with a
standard of care chemotherapy increasingly used in TNBC.
In summary, our work describes an integrated CNA and gene expression-driven
gene dependency identification and functional validation approach that
identifies novel malignant cell selective addictions, potential targetable genes or
pathways and associated patient selection biomarkers in TNBC. We reveal a
number of genes, biological processes, and clusters of interacting proteins that
merit further investigation. In particular, we identify and mechanistically
validate KIFC1, a potentially druggable kinesin, as a highly selective malignant
cell target, with mechanistic evidence of synergy in combination with cisplatin.
Furthermore, we developed a potential patient selection centrosome abnormality
biomarker appropriate for analysis of formalin-fixed tumor material that is
associated with KIFC1 addiction.
Methods
Patient demographics
All procedures performed in studies involving human participants were in
accordance with the ethical standards of the institutional and/or national
research committee and with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards. Access to pseudo-anonymized
samples and clinical data was obtained in accordance with the principles of the
Guy’s and St Thomas’ Research Tissue and Data Bank (REC No
07/H0804/131). Fresh-frozen needle macro-dissected invasive ductal
carcinomas obtained from 191 breast cancer patients with no prior therapy at
diagnosis and control tissue from reduction mammoplasties, and peripheral
blood lymphocytes were obtained from King’s Health Partners Cancer Biobank.
The patient demographics and clinico-pathological information have been
previously published[14, 15, 56] and are described in Supplementary Data 1.
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Immunohistochemistry on tumor samples
IHC expression of ER, PR, HER2, EGFR, and CK5/6 were assessed on
triplicate tissue microarrays (TMA) and reviewed by two pathologists. The
tissue was formalin-fixed, processed and paraffin-embedded using routine
protocols. Three-micron sections were cut and stained with hematoxylin and
eosin (Dako). Standard IHC protocols were used. Antigen retrieval was carried
out using citric acid buffer pH 6 (Dako). For visualization of nuclei,
hematoxylin counterstain was used. Secondary antibodies conjugated to
horseradish peroxidase (HRP) (Dako) were used for visualization with 3,3-
diaminobenzidine (DAB) (Dako), according to manufacturer’s protocol.
Microarray-based gene expression and copy number
profiling
Gene expression and copy number profiles were generated using Affymetrix
Human Exon 1.0ST and SNP6.0 arrays (E-MTAB-5270 and E-MTAB-2626) and
data was processed using specific gene expression and copy number pipelines
from Aroma Framework[15, 16, 39, 56, 57, 58, 59]. The data comprised 140
ER-negative and HER2-negative, 21 HER2-positive, 21 ER-positive breast
carcinomas, and 9 RNA samples derived from organoids of reduction
mammoplasties. ER and HER2 IHC-based expression levels were confirmed by
gene expression for each sample.
Target ID data platform
A gene-centric database was compiled (Supplementary Data 2), encompassing
information from five different categories: (A) gene expression block, (B) copy
number block, (C) copy number-gene expression association block, (D) clinical
annotation block, and (E) gene annotation block using publicly available
databases such as COSMIC[17], the Membranome[18], the Druggable
Genome[19], Secretome[20], CAN genes[21], and Kinome[22]. At our first
filter, we eliminated genes with weak correlation between gene expression and
copy number. We therefore identified genes which had a gain (absolute copy
numbers ≥ 2.38 based on cbs-segmented copy number) in at least 10% of TNBC
cases, and which gene expression showed a Spearman’s rank correlation of at
least 0.3 with a p-value of at least 0.01.
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These genes were included in our Target ID platform, consisting of (A) the
“gene expression block”, capturing the fold change and the significance of
differential gene expression between TNBC and normal mammary gland tissue,
all tumors and normal mammary gland tissue as determined by the limma
analyses[60], and the frequency of samples in which the respective gene had
expression levels twice as high as in the normal mammary gland tissue. (B) The
“copy number block”, reporting for each gene the frequency of copy number
gain/amplification in TNBCs, the average copy number levels in TNBC, and the
focality of CNA determined by GISTIC[61]. (C) The “copy number-gene
expression association block”, states the Spearman’s rank correlation between
each genes copy number and gene expression; and a multi-Mann–Whitney U
test using categorical copy number states as the grouping variable and the
expression of the gene as the dependent variable as previously described[62].
Benjamini and Hochberg adjusted p < 0.05 were considered significant[63]. (D)
The “clinical annotation block”, reporting fold change and p-value of
differential gene expression between TNBC with and without recurrences as
determined by limma[60]. (E) The “ gene annotation block” collated publicly
available information such as: gene description; mutational status in cancer
derived from COSMIC[17]; cell surface protein location and length of the
extracellular domain retrieved from Membranome[18]; druggability potential
retrieved from “the druggable genome”[19]; other information such as
Secretome[20], CAN genes[64], and Kinome[22]. Supplementary Data 2 lists
all of these features, their block affiliation, block description, priority
weighting, thresholds, and scores.
The feature weighting module assigned scores for each feature in the binning
approach. If the feature value is smaller than threshold1, then it is assigned a 0
score, if it lies between theshold1 and threshold2 it is assigned Score 1, if it is
greater than threshold2 it gets Score 2. The aggregated scores are reported for
each individual gene. The features are then combined to make five different
blocks of features and a limit on total block score is assigned for each block in
order to minimize the bias towards any specific block. The aggregated scores
from each block are then normalized with respect to the block limit and their
summation is reported as block normalized score.
Cell lines
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BCCLs were obtained from the ATCC and HMEC from Life Technologies.
Growth conditions were as recommended by the suppliers. Cells were
authenticated by short tandem repeat (STR) analysis and matched to the
German Collection of Microorganisms and Cell Cultures (DSMZ), and they
were used for no more than 25 passages after STR typing. Mycoplasma tests
were routinely performed using MycoAlert Mycoplasma Detection Kit (Lonza).
Although MCF7 and BT20 are included in the database of commonly
misidentified cell lines, they were authenticated by STR, and we included them
in our work as part of a comprehensive validation.
Breast cancer cell line gene expression data
Gene expression for 25 BCCLs based on the Illumina Human WG-6v2.0 and for
27 BCCLs based on the Affymetrix Human Exon 1.0ST microarrays were
reported previously[24, 39], with 20 BCCLs common to both data sets. Both
normalized gene expression cohorts were independently median-centered.
Target ID data platform and algorithm
A gene-centric database was compiled (Supplementary Data 2). This
encompassed information from five different categories: (A) gene expression
block, (B) copy number block, (C) copy number-gene expression association
block, (D) clinical annotation block, and (E) gene annotation block using
publicly available databases such as COSMIC[17], the Membranome[18], the
Druggable Genome[19], Secretome[20], CAN genes[21], and Kinome[22].
To identify potential CNA-regulated addiction genes for TNBC malignant
phenotypes, genes with cbs-smoothed Log  ratio ≥2.38 in ≥10% TNBCs were
selected. We then selected those with Spearman’s rank correlation between
expression and copy number data ≥0.30 and p > 0.01 in the TNBCs in our
discovery cohort were taken forward. Next genes were assigned a score that was
derived through a custom defined weighted evaluation of the five blocks in the
Target ID Data Platform (Supplementary Data 3). All code for the algorithm
used was implemented using the R statistical language.
RNAi-based functional validation
Gene “lots” and their assigned cell lines were established as follows: the three
2
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highest and lowest expressing BCCLs for each gene were determined. Those
genes having at least one cell line in common, among the highest and lowest
expressing cell lines, were grouped into gene “lots”. Thus, the candidate genes
were divided into five lots each to be tested in 6 to 9 breast cell lines, resulting
in a total of 16 BCCLs, and on one non-malignant cell line HMEC
(Supplementary Figure 1).
The “top 10” gene set was grouped into a separate lot and siRNA-mediated
knockdown was carried out by transfection of three siRNAs (Ambion)
independently at a concentration of 50 nM. Cells were plated in 96-well plates
and cell viability assays were performed in eight cell lines over three rounds
using CellTiter-Blue Cell Viability Assay (Promega) over 6-days and gene
knockdown by each siRNA was assessed by RT-PCR.
For the remaining five lots, siRNA-mediated knockdown was carried out by
transfection of pools of four siGenome siRNAs (Dharmacon) targeting the same
gene, at the total concentration of 50 nM. Cell viability assays were performed
in three rounds for each gene lot using the CellTiter-Blue Cell Viability Assay
(Promega) over 6-days. After normalization against the plate median and
correlation between the three rounds analyzed (Supplementary Data 10), the
data from the three rounds were pooled and the mean was plotted ± SEM.
siRNA against PLK1 and scrambled “non-silencing” siRNAs were used as
positive and negative controls, respectively.
The effect on cell viability was expressed as NPI where:
NPIx is the NPI of the x sample and µ  and µ  are the averages of positive
or negative controls, respectively, within that plate.
From the top ten gene list, genes having at least two siRNAs with KD ≥ 70%
showing an NPI < 18.01% in HMEC and an NPI ≥ 18.01% in at least two
malignant cell lines were considered as validated. For the remaining lots, genes
showing NPI < 18.01% in HMEC and an NPI ≥ 18.01% in at least two
malignant cell lines, or if they had an NPI ≥ 18.01% in HMEC then have an
NPI < 18.01% in at least two malignant cell lines and an NPI ≥ 18.01% in at
NPIx% = (x − ) / ( − ) × 100μneg μpos μneg
pos neg
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least two malignant cell lines were considered as passing the primary functional
validation experiment.
Quality control of the siRNA candidate screen
Prior to carrying out the functional validation experiments, siRNA transfection
conditions were optimized for each cell lines such that PLK1 siRNAs produced
a >70% reduction in CellTiter-Blue readings after 6 days compared to non-
silencing siRNA with minimal transfection reagent toxicity. Experiments were
carried out in 96-well plates, excluding the use of more external rows and
columns, to avoid edge effects (Supplementary Figure 2b). To achieve higher
data robustness, multiple positive and negative controls were added to each
plate and each round of the validation consisted of triplicate plates. A good
separation between positive and negative controls was also seen across all cell
lines (Supplementary Figure 2b). Position dependent effects were ruled out.
Valid experiments had a Z’ factor ≥0.3 and replicates were excluded if the r
between them and other replicates were <0.5. Overall the mean r  values for all
replicates within the analysis were 0.7, indicative of good quality data
(Supplementary Data 4).
Secondary functional validation
Single oligo deconvolution of the pooled siRNA from the primary functional
validation experiments were performed by grouping the genes in “lots”, each to
be tested against a small number of cell lines which appeared in the primary
validation to be relatively more addicted to some of the genes in that lot. Each
of the four individual oligos were assessed for both knockdown efficiency, by
RT-PCR, and effect on cell viability and the results integrated. Genes having
more than one individual siRNA sequence showing NPI < 18.01% despite KD ≥ 
70% were considered as a fail. Those genes for which at least two siRNAs
showed KD ≥ 40% and an NPI ≥ 18.01% were considered as validated.
Centrosome scoring
Confocal imaging of a panel of BCCLs generated centrosome amplification
2
2
= factor = 1 −Z ′ 3SDof pos controls + 3SDof neg controlsmean of pos controls − mean of neg controls
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score. Cells were double immunostained with α-IAK1 (BD Biosciences) and α-
CP110 (gift from E. Nigg) for centrosomes and centrioles, respectively. Cells
were counted as centrosome-amplified if they had more than two centriole
markers per centrosome and/or if they had more than two centrosomes per cell.
Centrosome amplification score was calculated as the percentage of
centrosome-amplified cells. For cisplatin-treated cells, centrosomes were scored
using the Perkin Elmer Operetta High Content Imaging System (Perkin Elmer)
and Harmony (Perkin Elmer).
Multipolar mitosis assay
Cells were plated in 96-well plates and transfected with individual
oligonucleotides (10 nM) including non-silencing negative control. Knockdown
of target gene was confirmed by western blot 72 h post-transfection and cells
were fixed in methanol and stained with α-IAK1 as a mitotic spindle marker.
Image acquisition was performed using the Perkin Elmer Operetta High Content
Imaging System (Perkin Elmer) and analyzed using Harmony (Perkin Elmer).
Mitotic cells with more than two mitotic spindle poles were scored as
multipolar and the percentage of multipolar mitoses was calculated from all
visible mitoses in a well of a 96-well plate (n > 100 for each replicate).
Time-lapse microscopy
MDA-MB-231 stable inducible NT and KIFC1 shRNA cells were transduced a
constitutive lentiviral vector expressing a mCherry-tagged histone H2B as a
fluorescent DNA marker. The cells were treated with doxycycline for a 72-h
period to ensure full expression of the shRNA before the start of the live-cell
imaging. Image acquisition was performed using Nikon Eclipse TE2000 with a
Hamamatsu Digital Camera. Images were acquired with a ×20 objective and
images were taken every 4 min for 50 h. Mitotic cells were scored as either
bipolar or multipolar and normal or apoptotic.
Animal studies
All applicable international, national, and/or institutional guidelines for the care
and use of animals were followed. All procedures performed in studies
involving animals were in accordance with the ethical standards of the
institution or practice at which the studies were conducted. All animal
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experiments were approved by the King’s College London Institutional
Committees on Animal Welfare (Animal Welfare and Ethical Review Body) and
in compliance with the United Kingdom Home Office Animals Scientific
Procedures Act, 1986. Female CD-1 Nu/Nu mice were obtained from Charles
River UK Ltd. Procedures were carried out after 20–35 days of age, mice were
maintained behind a barrier facility and handled in accordance with local
guidelines. One million MDA-MB-231 or HCC1954 stable inducible NT and
KIFC1 shRNA cells were injected into the right inguinal mammary fat pad of
mice following standard procedures. When tumors reached 2 × 2 mm (4.2 mm )
(as assessed by palpation and caliper measurement) mice were randomized into
two groups and one group were fed chow ad libitum containing Doxycycline at
625 mg kg  (Harlan Teklad Diets). Tumor growth was monitored over time
(assessed by palpation and caliper measurement). When the first control tumors
reached 10 mm in diameter, all mice for that experiment were culled and tumors
were excised and snap-frozen or processed for IHC (FFPE). Tumor volume was
calculated using the formula:  V = (π × length × width /6) This should be inserted
as an equation as the above two. , where the length is the largest tumor diameter
and width is the perpendicular diameter. Statistical analysis was performed
using Prism.
Immunohistochemical analysis
All primary antibodies used in this study are shown in Supplementary Data 12.
All the histological samples were scanned at ×20 (0.46 µm per pixel), except
with Pericentrin staining which were scanned at ×40 (0.25 µm per pixel) digital
magnification using Hamamatsu Nanozoomer 2.0 HT (Hamamatsu). The IHC
assessment was performed using semi-automated Image Analysis software
HistoQuest 4.0 (TissueGnostic).
Pericentrin staining was assessed in mitotic cells by a trained histopathologist.
The mitoses were scored as having either normal centrosomes or abnormal
centrosomes. Abnormal centrosomes were defined by either size (twice the
diameter of centrosomes in normal breast epithelium) or number (>2)
(Supplementary Figure 5c). Mitoses were further classified by polarity based on
the orientation of DNA and centrosomes in a cell. Mitotic cells with abnormal
centrosomes fell within the category of bipolar, multipolar, or those with diffuse
pericentrin and no polarity.
3
−1
2
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Pericentrin abnormality score
HistoQuest image analysis software was set up to count the number of
pericentrin events and staining area per event for cell line pellets, whole tissue
sections and TMAs. PCAB score was developed using by using a cut-off for
normal centrosome size (7 µm ) defined by analysis of pericentrin centrosome
size in normal breast tissue. The score is the number of abnormal pericentrin
bodies as a percentage of total bodies within a selected field. For whole sections
the tumor region was selected as the field of interest. For cell pellets and TMAs
the entire section or core, respectively, was selected as the field of interest with
at least 20 pericentrin bodies being score per case (average 440 pericentrin
bodies being scored per case).
KIFC1 si and shRNA sequences
KIFC1 siRNA #1: GGACUUAAAGGGUCAGUUA, KIFC1 siRNA #2:
GUGCUAAGAUGCUCAUGUU, KIFC1 siRNA #3:
GGAGCUCACUGUCACCAAU, KIFC1 siRNA #4:
UGACCUAAAUGCAGAACUA, KIFC1 siRNA #5:
CUCUACGCUUUGCCUCCAA, KIFC1 siRNA #6:
GUAGAGAUCUACAAUGAGA, KIFC1 shRNA:
AAGCTACGTAGAGATCTACAAT.
Generation of stable inducible NT and KIFC1 shRNA cell
lines
Oligonucleotides with both NT and KIFC1-targeting (KIFC1 shRNA) shRNAs
with flanking AgeI and EcoRI restriction sites were cloned into the Tet-pLK0-
puro plasmid (a gift from Dmitri Wiederschain via Addgene). Lentiviral
particles were subsequently produced by transfecting HEK293T cells with the
plasmid and lentiviral packaging vectors pSPAX2 and pMD2.G. Next, CAMA1,
BT20, HCC1954, and MDA-MB-231 were infected with the lentivirus and then
cultured in the presence of 1.5 µg ml  puromycin. Knockdown was confirmed
in vitro by addition of 1 µg ml  doxycycline for 72 h followed by Western blot.
Colony formation assays
Surviving fraction of cells was analyzed using colony formation assays. Cell
2
−1
−1
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lines expressing the inducible vectors were generated as above. Cells were
plated at low density and shRNA expression was induced by addition of
doxycycline. Knockdown of target gene was confirmed by Western blot 96 h
post-transduction and colonies were fixed with ice-cold methanol and stained
with 0.5% crystal violet at 14 days post-transduction. Colony size was defined
as a minimum of 50 cells and colonies were counted using BIO-RAD
XRS+system (BIO-RAD) and Image Lab XRS+software (BIO-RAD).
Statistical analysis
Gene expression and copy number statistical analyses were performed in the R
environment as described above. For in vitro studies, no samples were
processed and then excluded; all completed experiments are reported. Unpaired
two-sided t-tests and one-way ANOVA with Tukey’s multiple comparison were
performed using GraphPad Prism software for analysis of all in vitro and in
vivo studies. For in vivo studies, we estimated that we would need at least six
samples per treatment group to see an effect, for a power of 80% and for a
probability of Type I error (α) = 0.05. Experiments were repeated at least twice
to confirm treatment response. The total number of mice per group is indicated.
Mice were excluded from the study if body weight was reduced during
treatment by more than 15% as compared to that at the start of treatment.
Investigators were blinded to the group allocation during the experiment and
drug treatment. Investigators were also blinded when assessing the outcome by
IHC. Mice were randomized to treatment groups when tumors reached a
predetermined diameter on a per experiment basis, as described above. The
sample size for all in vitro experiments were not chosen with consideration of
the power needed to detect a pre-specified effect size. For each data set, the data
meet the assumptions of the statistical test used, as determined by distribution
and variance.
Data availability
All data is available from ArrayExpress (https://www.ebi.ac.uk/arrayexpress/)
under following accession codes (E-MTAB-5270 and E-MTAB-2626), and can
be interrogated via our web portal upon request.
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